Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | PPP5C | P53041 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2159391 | 1.00 | APLNR (0.37) | APLNRCYP2C19GABRR1CYP2D6CYP1A2 | |
| SCHEMBL2158824 | 1.00 | APLNR (0.37) | APLNRCYP2C19GABRR1CYP2D6CYP1A2 | |
| SCHEMBL20572944 | 1.00 | APLNR (0.37) | APLNRCYP2C19GABRR1CYP2D6CYP1A2 | |
| SCHEMBL19506520 | 0.88 | APLNR (0.41) | APLNRCYP2C19GABRR1CYP2D6CYP1A2 | |
| SCHEMBL850635 | 0.84 | APLNR (0.43) | APLNRCYP2C19GABRR1CYP2D6CYP1A2 | |
| SCHEMBL850636 | 0.84 | APLNR (0.43) | APLNRCYP2C19GABRR1CYP2D6CYP1A2 | |
| SCHEMBL6943949 | 0.82 | APLNR (0.39) | APLNRCYP2C19GABRR1CYP2D6CYP1A2 | |
| SCHEMBL6943955 | 0.82 | APLNR (0.39) | APLNRCYP2C19GABRR1CYP2D6CYP1A2 | |
| SCHEMBL13631043 | 0.81 | ACE (0.39) | APLNRCYP2C19GABRR1PPP5CTSHR | |
| SCHEMBL10265765 | 0.81 | ACE (0.39) | APLNRCYP2C19GABRR1PPP5CTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473518-B | Bisphosphonic acid compounds | 株式会社富士药品 | 2021-07-06 | — | — | CN | disclosed |
| US-10689408-B2 | Bisphosphonic acid compound | FUJIYAKUHIN CO., LTD. (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20200048183-A1 | ANTIMICROBIAL AGENTS | UNIV WARWICK (GB) | 2020-02-13 | — | — | US | disclosed |
| US-20190002482-A1 | NOVEL BISPHOSPHONIC ACID COMPOUND | FUJIYAKUHIN CO., LTD. (JP) | 2019-01-03 | — | — | US | disclosed |
| EP-3409679-A1 | NOVEL BISPHOSPHONIC ACID COMPOUND | Fuji Yakuhin Co., Ltd. (JP) | 2018-12-05 | — | — | EP | disclosed |
| EP-2471773-B1 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2471773-A1 | Piperidinyl derivatives as modulators of chemokine receptor activity | Bristol-Myers Squibb Company (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-2471774-A1 | Piperidinyl derivatives as modulators of chemokine receptor activity | Bristol-Myers Squibb Company (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20110245226-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-7985861-B2 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-26 | — | — | US | disclosed |
| CN-101600691-A | Acyclic derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2009-12-09 | — | — | CN | disclosed |
| US-20090298833-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-03 | — | — | US | disclosed |
| US-7601844-B2 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| EP-2049486-A2 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20070208056-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
| WO-2007092681-A2 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298833-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | APLNR 496/4885CYP2C19 2288/4885GABRR1 125/4885 |
| US-20200048183-A1 | ANTIMICROBIAL AGENTS | C3AR1, HCAR3, C5AR1 | APLNR 339/4885CYP2C19 1240/4885GABRR1 385/4885 |
| US-20070208056-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | APLNR 496/4885CYP2C19 2288/4885GABRR1 125/4885 |
| US-10689408-B2 | Bisphosphonic acid compound | SOST, PTH1R, BMP2 | APLNR 589/4885CYP2C19 2391/4885GABRR1 1073/4885 |
| US-20110245226-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | APLNR 496/4885CYP2C19 2288/4885GABRR1 125/4885 |
| US-20190002482-A1 | NOVEL BISPHOSPHONIC ACID COMPOUND | SOST, PTH1R, BMP2 | APLNR 511/4885CYP2C19 2638/4885GABRR1 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.